2018-19 Section 7-Neoplastic and Inflammatory Diseases of the Head and Neck eBook

Head and neck oncology

17. Balheda R, Braiteh FS, Balmanoukian AS, et al. Long-term safety and clinical outcomes of atezolizumab in head and neck cancer: phase Ia in trial results. Ann Oncol 2017; 28(Suppl 5):v372–v394. 18. Zandberg D, Algazi A, Jimeno A, et al. Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): preliminary results from a single-arm, phase 2 study. Ann Oncol 2017; 28(Suppl 5): v372–v394. 19. Rimm DL, Han G, Taube JM, et al. A prospective, multiistitutional pathologist- based assessment of 4 immunohistochemistry assays for PD-L1 expression in nonsmall cell lung cancer. JAMA Oncol 2017; 3:1051–1058. 20. NCT02626000 talimogene laherparepvec with pembrolizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (MASTERKEY237/ KEYNOTE-137). https://clinicaltrials.gov/ct2/show/NCT02626000. [Accessed 1 February 2018]. 21. & Saba NF, Mody MD, Tan ES, et al. Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy. Crit Rev Oncol Hematol 2017; 115:50–58. This article summarized the safety profile of immunotherapies in HNSCC.

13. Baxi SS, Dunn LA, Burtness BA. Amidst the excitement: a cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma. Oral Oncol 2016; 62:147–148. 14. Harrington KJ, Ferris RL, Blumenschein G Jr, et al. Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squa- mous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol 2017; 18:1104–1115. 15. && Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carci- noma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 2016; 17:956–965. This was the first published trial demonstrating a clinical activity in HNSCC from immunotherapy. 16. Cohen E, Harrington KJ, Le Tourneau C, et al. Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): phase 3 KEYNOTE-040 trial. Ann Oncol 2017; 28(Suppl 5):v605–v649.

www.co-otolaryngology.com

Volume 26 Number 2 April 2018

227